Contact
searchSearch
HMP Global
Login
Videos

Evaluating Oral SERDs in HR-Positive, HER2-Negative Breast Cancer

Seth Wander MD, PhD
03/18/2026


At Great Debates Solid Tumors in Miami, Florida, Seth Wander, MD, PhD, from Massachusetts General Hospital, Boston, Massachusetts, discusses whether emerging oral selective estrogen receptor degraders (SERDs) differ meaningfully in HR-positive, HER2-negative breast cancer. 

Dr Wander reviews clinical and translational data, highlighting that oral SERDs demonstrate similar efficacy, resistance patterns, and toxicity profiles across trials, while emphasizing the need for biomarker-driven strategies and ongoing phase 3 data to better define their role in clinical practice.

Source: 

Wander S. Oral SERDs in breast cancer: They’re all the same: Yes vs no. Presented at Great Debates - Solid Tumors; Miami, Florida. March 14-15, 2026. 

© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.

Related Content

Sami Diab, MD
Videos
Updated NCCN Guidelines Strengthen Support for Breast Cancer Index® in Extended Endocrine Therapy Decision-Making
01/23/2026
Sami Diab, MD
Sami Diab, MD, discusses recent updates to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer, which reinforces the Breast Cancer Index® as the only genomic test predictive of benefit from extended endocrine therapy in...
Sami Diab, MD, discusses recent updates to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer, which reinforces the Breast Cancer Index® as the only genomic test predictive of benefit from extended endocrine therapy in...
Sami Diab, MD, discusses recent...
01/23/2026
Oncology
Joseph Sparano, MD
Conference Coverage
Multimodal AI Model Strengthens Prognostic Accuracy for Late Distant Recurrence in HR-Positive, HER2-Negative Early Breast Cancer
12/18/2025
Joseph Sparano, MD
Joseph Sparano, MD, discusses new findings from the TAILORx multimodal AI analysis, which identified that multimodal AI models, particularly the ICM+ model, significantly outperformed traditional models for predicting late distant recurrence...
Joseph Sparano, MD, discusses new findings from the TAILORx multimodal AI analysis, which identified that multimodal AI models, particularly the ICM+ model, significantly outperformed traditional models for predicting late distant recurrence...
Joseph Sparano, MD, discusses...
12/18/2025
Oncology
Aditya Bardia, MD
Conference Coverage
Giredestrant Improves Survival Outcomes in ER-Positive, HER2-Negative Early-Stage Breast Cancer
12/18/2025
Aditya Bardia, MD
Aditya Bardia, MD, discusses results from the phase 3 lidERA trial showing giredestrant significantly improved invasive disease-free survival compared to standard endocrine therapy for patients with ER-positive, HER2-negative early-stage...
Aditya Bardia, MD, discusses results from the phase 3 lidERA trial showing giredestrant significantly improved invasive disease-free survival compared to standard endocrine therapy for patients with ER-positive, HER2-negative early-stage...
Aditya Bardia, MD, discusses...
12/18/2025
Oncology
Conference Coverage
Imlunestrant Plus Abemaciclib for HR-Positive, HER2-Negative Advanced Breast Cancer: EMBER-3 Trial
12/12/2025
Stephanie Holland
Updated results from the EMBER-3 trial show that imlunestrant, alone or with abemaciclib, provides clinically meaningful efficacy and manageable safety among previously treated patients with HR-positive, HER2-negative advanced breast cancer,...
Updated results from the EMBER-3 trial show that imlunestrant, alone or with abemaciclib, provides clinically meaningful efficacy and manageable safety among previously treated patients with HR-positive, HER2-negative advanced breast cancer,...
Updated results from the EMBER-3...
12/12/2025
Oncology

Recent News

FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG...
03/20/2026
Oncology
News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology
News
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
FDA Alerts
Ipsen Voluntarily Withdraws Tazemetostat Following Updated Safety Findings from the SYMPHONY-1 Trial
03/11/2026
Stephanie Holland
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data...
03/11/2026
Oncology
News
Pimicotinib Maintains Favorable Safety Profile in Tenosynovial Giant Cell Tumor
03/11/2026
Stephanie Holland
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the...
03/11/2026
Oncology
News
Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
FDA Approval
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use